Stefan Elbers

51 Evaluating IMPT programmes over time Table 3. Continued Outcome Pre - post Post - final follow-up Pre - post- final follow-up Pre- final follow-up N 1 Direction of effect 3 N 1 Mdn ES (range) Q test / I 2 N 1 Mdn ES (range) Q test / I 2 N 1 Pattern over time 2 N 1 Mdn ES (range) Q test / I 2 ANX 11 0.43 (0.11 to 3.77) HADS-A 2 : 1.87 Q (df =10 ) = 286.28*** I 2 = 99% 11 -0.02 (-1.61 to 0.73) Q (df = 10) = 61.62*** I 2 =97% 6 18 0.29 (.02 to 1.18) Q (df = 17) = 344.75*** I 2 = 92% 13 5 + +/- 3 1 1 EF 4 1.81 (0.48 to 2.99) SF36 MH 2 : 21.85 Q (df = 3 ) = 106.72*** I 2 = 98% 4 -0.01 (-0.34 to 0.66) Q (df = 3 ) = 39.42*** I 2 = 93% 2 9 0.62 (0.25 to 3.48) Q (df = 8) = 182.95*** I 2 = 99% 9 + 2 ANG 1 1.94 4 SCL-90h 2 : 3.88 NA 1 -0.49 4 NA 1 1 0.49 4 NA 1 + SE 7 0.77 (0.10 to 1.20) PSEQ 2 : 9.12 Q (df = 6 ) = 72.66*** I 2 = 90% 7 0.07 (-0.21 to 0.25) Q (df =6 ) = 5.19 I 2 = 0% 5 9 0.85 (0.16 to 1.30) Q (df =8 ) = 81.35*** I 2 =87% 8 1 + +/- 2